CStone Pharmaceuticals
CStone Pharmaceuticals (CSPHF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for CStone Pharmaceuticals (CSPHF), covering cash flow, earnings, and balance sheets.
CStone Pharmaceuticals (CSPHF) Income Statement & Financial Overview
Explore comprehensive income reports for CStone Pharmaceuticals CSPHF, broken down by year and quarter.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $76.52M | $76.52M | $127.08M | $127.08M |
| Cost of Revenue | $42.46M | $42.46M | $41.07M | $41.07M |
| Gross Profit | $34.06M | $34.06M | $86.01M | $86.01M |
| Gross Profit Ratio | $0.45 | $0.45 | $0.68 | $0.68 |
| R&D Expenses | $34.20M | $34.20M | $33.12M | $33.12M |
| SG&A Expenses | $51.07M | $51.07M | $54.72M | $54.72M |
| Operating Expenses | $85.27M | $85.27M | $87.84M | $87.84M |
| Total Costs & Expenses | $127.73M | $127.73M | $128.91M | $128.91M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $4.73M | $3.44M | $3.44M | $3.44M |
| EBITDA | -$41.12M | -$42.41M | $1.61M | $1.61M |
| EBITDA Ratio | -$0.54 | -$0.55 | $0.01 | $0.01 |
| Operating Income | -$51.21M | -$51.21M | -$1.83M | -$1.83M |
| Operating Income Ratio | -$0.67 | -$0.67 | -$0.01 | -$0.01 |
| Other Income/Expenses (Net) | -$2.24M | -$2.24M | $9.68M | $9.68M |
| Income Before Tax | -$53.45M | -$53.45M | $7.85M | $7.85M |
| Income Before Tax Ratio | -$0.70 | -$0.70 | $0.06 | $0.06 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$53.45M | -$53.45M | $7.85M | $7.85M |
| Net Income Ratio | -$0.70 | -$0.70 | $0.06 | $0.06 |
| EPS | -$0.04 | -$0.04 | $0.005 | $0.005 |
| Diluted EPS | -$0.04 | -$0.04 | $0.006 | $0.006 |
| Weighted Avg Shares Outstanding | $1.28B | $1.28B | $1.57B | $1.57B |
| Weighted Avg Shares Outstanding (Diluted) | $1.28B | $1.28B | $1.28B | $1.28B |
Financial performance has remained strong, with revenue growing from $127.08M in Q1 2024 to $76.52M in Q4 2024. Gross profit continued to perform well, with margins at 45% in the latest quarter. Operating income reached -$51.21M in Q4 2024, holding a steady -67% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$41.12M. Net income rose to -$53.45M, keeping EPS at -$0.04. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan